v3.26.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 03, 2024
USD ($)
performanceObligation
Dec. 12, 2021
USD ($)
Jul. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]                
Total revenue       $ 367 $ 211,246      
Accounts receivable       400     $ 3,567  
License revenue                
Disaggregation of Revenue [Line Items]                
Total revenue       0 195,355      
Service revenue                
Disaggregation of Revenue [Line Items]                
Total revenue             38,500  
Takeda Pharmaceuticals U.S.A., Inc. | License revenue                
Disaggregation of Revenue [Line Items]                
Upfront license fee $ 200,000              
Reimbursement from limited partnership investment 51,400              
Takeda Pharmaceuticals U.S.A., Inc. | License and Know-How                
Disaggregation of Revenue [Line Items]                
Upfront license fee 195,400              
Takeda Pharmaceuticals U.S.A., Inc. | Transition Services                
Disaggregation of Revenue [Line Items]                
Upfront license fee $ 56,100              
Hansoh Agreement | Hansoh Shanghai Healthtech Co Ltd                
Disaggregation of Revenue [Line Items]                
Total revenue   $ 18,000       $ 18,000    
Revenue, remaining performance obligation, development milestones, variable consideration       23,500        
Revenue, remaining performance obligation, sales milestones, variable consideration amount       $ 144,000        
Upfront license fee               $ 20,000
Withholding taxes from upfront fee               $ 2,000
License Agreement | Maximum                
Disaggregation of Revenue [Line Items]                
Term of the TSA fifteen              
License Agreement | Minimum                
Disaggregation of Revenue [Line Items]                
Term of the TSA six              
License Agreement | Hansoh Shanghai Healthtech Co Ltd                
Disaggregation of Revenue [Line Items]                
Expiration period       10 years        
License Agreement | Takeda Pharmaceuticals U.S.A., Inc.                
Disaggregation of Revenue [Line Items]                
Total revenue     $ 10,000          
Expiration period       10 years        
Accounts receivable       $ 300     3,600  
License agreement upfront fee $ 200,000              
Potential milestone, development based milestones       80,000        
Potential milestone payments, commercial-based milestones 280,000              
Potential milestone payments, sales-based milestones $ 740,000              
Number of performance obligations | performanceObligation 2              
Tech Transfer Agreement | Manufacturing Technology Transfer Agreement                
Disaggregation of Revenue [Line Items]                
Service revenue       0 100      
Supply Agreement | Hansoh Shanghai Healthtech Co Ltd                
Disaggregation of Revenue [Line Items]                
Accounts receivable       100     $ 0  
Supply Agreement | Clinical Product Supply Agreement                
Disaggregation of Revenue [Line Items]                
Upfront license fee       $ 300 $ 300